Your session is about to expire
← Back to Search
NMDA receptor antagonist
Ketamine plus usual care for Traumatic Injury (KAPT Trial)
Phase 4
Waitlist Available
Led By John P Harvin, MD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adult trauma patients
Admission to Shock Trauma ICU (STICU) or Surgical Intermediate Unit (SIMU)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post admission
Awards & highlights
KAPT Trial Summary
This trial looks at whether adding Ketamine to standard care can help manage pain in trauma patients, and how well patients tolerate this treatment.
Eligible Conditions
- Traumatic Injury
- Pain
- Opioid Use Disorder
KAPT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowKAPT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months post admission
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post admission
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Average Daily Opioid Use as Measured by the Morphine Milligram Equivalents (MME) Per Day
Secondary outcome measures
Duration of Ketamine Drip
Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Anxiety/Depression)
Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Current Health)
+22 moreKAPT Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Ketamine plus Usual careExperimental Treatment1 Intervention
Group II: Usual careActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine plus usual care
2020
Completed Phase 4
~310
Find a Location
Who is running the clinical trial?
The University of Texas Health Science Center, HoustonLead Sponsor
902 Previous Clinical Trials
320,634 Total Patients Enrolled
John P Harvin, MDPrincipal InvestigatorThe University of Texas Health Science Center, Houston
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger